Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning factors: a downward revision of the 2025 outlook, declining sales across segments, supply chain issues, and high SG&A costs. Despite strategic priorities and some brand successes, management's vague responses in the Q&A and lack of concrete guidance further dampen sentiment. The negative financial trends, combined with external pressures like tariffs and competitive challenges, suggest a negative stock price reaction in the short term.
Key Financial Performance
Organic Sales Declined 4.2% year-over-year. Reasons include unfavorable seasonal and customer inventory dynamics, soft allergy and sun care seasons, trade inventory fluctuations, and strategic investments in price in the U.S.
Adjusted Operating Margin Contracted 10 basis points year-over-year to 22.7%. This was due to softer gross margins offset by SG&A savings.
Adjusted Gross Margin Contracted 70 basis points year-over-year to 60.9%. Reasons include input cost inflation, unfavorable mix, currency impacts, and strategic price investments.
Adjusted Diluted EPS Decreased to $0.29 from $0.32 year-over-year. This was impacted by lower operating income and a higher adjusted effective tax rate.
Self Care Segment Organic Sales Declined 5.9% year-over-year. Reasons include lower volumes, soft allergy and sun care seasons, and inventory fluctuations in North America and Asia Pacific.
Skin Health and Beauty Organic Sales Decreased 3.7% year-over-year. Reasons include weak sun care category performance, strategic price investments, and declines in North America and Asia Pacific.
Essential Health Organic Sales Decreased 2.4% year-over-year. Reasons include cycling against a strong prior year, inventory fluctuations, and competitive pressures in certain regions.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Innovation pipeline: The company has the most robust pipeline of innovation in years, focusing on fewer, bigger, and better ideas.
New product launches: Tylenol Precise Nighttime and Children's Tylenol Natural Apple Flavor were launched to meet evolving consumer needs.
OGX Bond Protein Repair: This product has been the #1 performing innovation year-to-date, helping secure additional distribution for the brand.
Regional performance: Strong performance in EMEA and Latin America, with consumption growth in these regions.
Market share: 83% of the U.S. Self Care business held or gained share, with ZYRTEC and Tylenol showing strong performance.
Global campaigns: Listerine's 'Wash Your Mouth' campaign launched in the U.S. and activated in Canada, U.K., Germany, and China.
Leadership changes: Four new leaders, including a Chief Technology and Data Officer, were appointed in the past three months to strengthen capabilities.
Operational complexity: The company is addressing self-induced complexity, such as a long tail of SKUs that account for only 1% of sales.
Execution focus: Emphasis on flawless go-to-market execution, including category management, revenue growth management, and e-commerce.
Strategic review: A comprehensive review of strategic alternatives is underway, including optimizing the brand portfolio.
Consumer-centric mindset: Refocusing on household penetration and consumer insights to drive market share and innovation.
Cost optimization: Efforts to reduce SG&A costs and improve ROI on brand investments are in progress.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership and Strategic Direction: The company is undergoing significant leadership changes, including the appointment of an interim CEO and a new CFO, which may create uncertainty and disrupt strategic continuity. Additionally, the company is conducting a comprehensive review of strategic alternatives, which could lead to significant changes in operations or focus.
Operational Complexity: The organization faces significant complexity in its operations, including managing 115 brands, a long tail of SKUs contributing minimally to sales, and inefficiencies in innovation execution. This complexity hinders agility and decision-making.
Execution Challenges: The company has acknowledged poor execution in key areas, including go-to-market strategies, category management, and e-commerce. This has led to missed opportunities in market share and consumer engagement.
Financial Performance: The company reported a 4.2% decline in organic sales for Q2 2025, with underperformance across key segments like Self Care, Skin Health and Beauty, and Essential Health. This has led to a downward revision of the 2025 financial outlook.
Market and Consumer Dynamics: The company is facing challenges in adapting to changing consumer preferences and market dynamics, including a weak allergy and sun care season and competitive pressures in key markets like the U.S. and Asia Pacific.
Supply Chain and Inventory Management: Issues with demand forecasting, trade inventory fluctuations, and supply chain inefficiencies have negatively impacted financial performance and operational reliability.
Cost Structure and Efficiency: The company’s SG&A costs are above industry benchmarks, and there is a need for further cost optimization to improve margins and fund growth initiatives.
Regulatory and Economic Environment: The company is navigating a dynamic macroeconomic and regulatory environment, including tariffs that are expected to have a financial impact of $150 million annually.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Organic Sales: For 2025, organic sales are expected to decline in the low single digits, with a neutral impact from currency.
Adjusted Operating Margin: The adjusted operating margin is expected to contract due to strategic price investments, fixed cost deleverage, and inflationary pressures, which are not expected to be fully offset by productivity initiatives.
Tariff Impact: The gross annualized impact of tariffs is estimated to be around $150 million, with a lower impact in 2025 due to timing.
Adjusted Diluted EPS: Full-year adjusted diluted EPS is projected to be in the range of $1 to $1.05, including a low single-digit drag from currency.
Innovation Pipeline: The company plans to launch a robust pipeline of innovation in the back half of the year, which is expected to contribute to growth.
Cost Savings and Productivity: Urgent actions are being taken to curtail discretionary spending and accelerate productivity measures to address the top-line shortfall.
Revenue Growth Management: Strengthening revenue growth management capabilities with a focus on top markets and margin-enhancing innovation.
Brand Investments: The company plans to continue supporting its brands at a higher level than last year, with a focus on higher ROI ideas.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's approach to addressing complexity and focusing on key areas?
A:The company plans to focus on the biggest brands, countries, and innovations while addressing the complexity of long-tail SKUs that contribute less than 1% of sales. They aim to improve executional excellence in areas like e-commerce, core brand strength, and media ROI.
Q:What were the biggest surprises for Kirk Perry upon stepping into his role?
A:Kirk Perry was surprised by the self-induced complexity within the company, which hinders agility and results. He noted the potential of the company's iconic brands and highlighted areas of success, such as Tylenol's 12 consecutive quarters of growth and Aveeno Baby's 9 consecutive quarters of growth.
Q:What is the company's framework for addressing complexity and unlocking value?
A:The company is conducting a strategic alternatives review in conjunction with operational excellence efforts. They are focusing on execution, brand building, innovation, and go-to-market excellence while considering all potential value-creating alternatives.
Q:How will the company measure success in its restructuring efforts?
A:Success will be measured by sequential improvement in consumer purchases and market share. The company is focusing on leadership, capabilities, execution, and operating structure to achieve these goals.
Q:What are the potential headwinds and restructuring costs associated with reducing complexity?
A:The company is addressing operational complexity, such as SKU reduction, but it is too early to comment on the specifics of restructuring costs. They are also conducting a strategic review to inform future choices.
Q:What is the updated guidance for the company's top-line and margins?
A:The company expects a low single-digit decline in top-line growth for the full year, with potential improvement in Q4 due to easier comparisons. Margins are expected to contract due to factors like tariffs and reinvestments.
Q:What are the trends and factors affecting Q3 performance?
A:Q3 trends are similar to Q2, with consumption ahead of organic sales. Seasonal businesses remain weak, and the company is factoring in U.S. retailer inventory destocking and China supply chain disruptions into its guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on potential business divestitures, restructuring costs, and the exact timing of improvements or strategic decisions. They also used broad language when discussing the strategic review and operational changes, without committing to concrete actions or outcomes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America Asia
Amit Banati
Asia Pacific
CEO
EMEA Latin
Face
Health Beauty
Latin America
North
Research Division
SGA
Self Care
Tylenol
adult
company
consumption
customer
date
dive
driver
experience
focus
fundamental
household penetration
idea
insight
market share
moment truth
period
potential
product
review alternative
technology
truth consumer
work
KVUE Transcript
Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call reveals several concerning factors: a downward revision of the 2025 outlook, declining sales across segments, supply chain issues, and high SG&A costs. Despite strategic priorities and some brand successes, management's vague responses in the Q&A and lack of concrete guidance further dampen sentiment. The negative financial trends, combined with external pressures like tariffs and competitive challenges, suggest a negative stock price reaction in the short term.
Kenvue Inc. (NYSE:KVUE) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents mixed signals. While EPS exceeded expectations and there is optimism for the second half of the year, current financial metrics such as declining organic sales and margins pose concerns. The lack of a shareholder return plan and supply chain challenges also weigh negatively. However, the company's innovation and strategic initiatives, along with positive consumer responses, provide a balanced outlook. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction for the next two weeks.
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
Unknown5-8
The earnings call reflects a challenging financial situation with declining organic sales, adjusted gross margin, and operating margin. The absence of a share buyback or dividend program further dampens investor sentiment. While management expressed optimism about innovation and growth in the latter half of the year, the lack of specific guidance and clarity in responses, particularly concerning tariff impacts and innovation success tracking, adds uncertainty. The overall sentiment is negative due to these factors, despite some positive consumer response and planned strategic investments.
Kenvue Inc. (NYSE:KVUE) Q4 2024 Earnings Call Transcript
Unknown2-7
The earnings call highlights several challenges: weak organic sales growth, distribution issues in Asia Pacific, and economic uncertainties. The lack of a share repurchase program and the operational separation risks add to investor concerns. Despite some positive elements like increased gross margin and brand investment, the overall sentiment is negative due to the financial outlook and management's vague responses during the Q&A. The absence of any strong positive catalysts, such as a new partnership or robust guidance, further supports a negative sentiment.
KVUE Slides
KVUE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
